KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Thoracoscopy-guided thoracic paravertebral block using dexmedetomidine in combination with ropivacaine for postoperative analgesia after thoracoscopic radical resection of lung cancer: a randomized controlled trial. PMID 40343511 · J Cancer Res Clin Oncol · 2025-May-09 While the study is a randomized trial of a drug intervention in an oncology population, it is excluded because it does not meet the required time-to-event efficacy endpoint for a cancer trial (the primary endpoint is an analgesia measure) and the trial phase is not confirmed as definitive (Phase III/IIIb or Phase II/III).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial. PMID 39827881 · Med · 2025-May-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network. PMID 40349134 · Oncologist · 2025-May-08 The study is a retrospective observational cohort analysis, not a randomized Phase III/IIIb or Phase II/III trial with a drug intervention. While it reports oncology, human, drug intervention, and time-to-event endpoints, it fails the core criteria of being a randomized trial of a definitive phase.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab. PMID 40341029 · J Immunother Cancer · 2025-May-07 The record describes a secondary, post-hoc predictive modeling study from the phase III IMvigor211 trial, focusing on identifying primary refractory disease using baseline and early-treatment parameters. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with survival analysis (Kaplan-Meier, HR). The analysis is a binary classification of refractoriness, not a time-to-event outcome.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of the aldehyde dehydrogenase 2 (ALDH2) gene testing on alcohol drinking behaviors among the Chinese Han population: study protocol of a single-center, open-label, randomized, controlled clinical trial. PMID 40336132 · Trials · 2025-May-07 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial. PMID 40335980 · BMC Cancer · 2025-May-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
PROtective ileoStomy versus ProtectivE colostomy in anterior Rectal resectIon: study protocol for a multicenter, open-label, randomised conTrolled studY (PROSPERITY). PMID 40335149 · BMJ Open · 2025-May-06 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
8MW0511, a novel, long-acting granulocyte-colony stimulating factor fusion protein for the prevention of chemotherapy-induced neutropenia: final results from the phase III clinical trial. PMID 40329331 · Breast Cancer Res · 2025-May-06 Study meets criteria for oncology, human, randomized, Phase III, drug intervention, and original report, but lacks a time-to-event efficacy endpoint (OS/PFS/DFS/EFS/RFS/TTP or HR/Kaplan-Meier analysis). The primary endpoint is duration of severe neutropenia, which is not a time-to-event outcome per the adjudication rules.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
History of Cancer and Atrial Cardiopathy: A Secondary Analysis of the ARCADIA Clinical Trial. PMID 40265582 · J Am Heart Assoc · 2025-May-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
SEARCH Study: Text Messages and Automated Phone Reminders for HPV Vaccination in Uganda: Randomized Controlled Trial. PMID 40324213 · JMIR Mhealth Uhealth · 2025-May-05 This is a pilot randomized controlled trial of a reminder system (text messages/phone calls) for HPV vaccination. While related to cancer prevention, it does not meet the inclusion criteria for an oncology therapeutic trial: it is not a drug-containing intervention (vaccination reminder, not drug), not a Phase III/IIIb or Phase II/III trial (pilot study), and the primary endpoint is vaccination timeliness, not a time-to-event efficacy endpoint (OS, PFS, etc.) for a diagnosed malignant neoplasm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
High mortality among fishermen along the beaches of lake Victoria: secondary analysis of evidence from a randomized control trial to promote HIV testing and services uptake in Siaya County, Kenya. PMID 40316987 · BMC Public Health · 2025-May-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The Effect of Surgeon Experience on the Recurrence of Non-Muscle Invasive Bladder Cancer (NMIBC), Following Transurethral Resection of the Bladder Tumor (TURBT): A double Blinded Prospective Randomized Study. PMID 40439390 · Asian Pac J Cancer Prev · 2025-May-01 Study is a randomized trial on surgical technique in oncology, but lacks a drug intervention and a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of Structured Exercise-based rehabilitation on Sarcopenia and Quality of life among Head and Neck Cancer Patients Undergoing Chemo-radiotherapy: A Randomized Controlled Trial. PMID 40439377 · Asian Pac J Cancer Prev · 2025-May-01 The study is an oncology RCT in humans with a primary result, but it is not eligible because it does not involve a drug-containing intervention (exercise is non-drug), does not report a time-to-event efficacy endpoint (outcomes are changes in sarcopenia and QOL scores), and the phase (III/IIIb or II/III) is not established.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized-Controlled Trial Comparing Safety and Efficacy of Repairing Balm vs Topical Antimicrobial for Post-Procedural Wounds. PMID 40327581 · J Drugs Dermatol · 2025-May-01 The study is a randomized trial on wound healing for actinic keratoses (pre-cancerous), not a Phase II/III or Phase III/IIIb trial of a drug-containing intervention for human malignant neoplasm with a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease. PMID 40315028 · Am J Gastroenterol · 2025-May-01 The study is a randomized trial with a time-to-event primary endpoint and drug intervention, but it focuses on Crohn's disease, which is not an oncology indication (human malignant neoplasm). Therefore, it is excluded from the oncology KM digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA Study. PMID 40147846 · J Nucl Med · 2025-May-01 The study is a randomized controlled trial in oncology (prostate cancer) with a drug intervention, but it is not eligible because the primary outcome is not a time-to-event endpoint with reported KM/HR analysis, and the phase is not explicitly confirmed as Phase III. The report is a secondary subgroup analysis.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Cocoa Flavanol Supplementation and Risk of Age-Related Macular Degeneration: An Ancillary Study of the COSMOS Randomized Clinical Trial. PMID 40146119 · JAMA Ophthalmol · 2025-May-01 The study is a randomized trial of a dietary supplement for age-related macular degeneration, not a drug intervention for human malignant neoplasm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Precision Exercise Effect on Fatigue and Function in Lung Cancer Surgery: A Randomized Clinical Trial. PMID 40072448 · JAMA Surg · 2025-May-01 The study is a randomized Phase 3 trial in lung cancer patients, but it evaluates an exercise intervention (non-drug) and uses functional/fatigue endpoints, not time-to-event efficacy endpoints required for this cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial. PMID 40015919 · J Nucl Med · 2025-May-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study. PMID 39998850 · Clin Cancer Res · 2025-May-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies. PMID 39892885 · J Rheumatol · 2025-May-01 The record describes a Phase III randomized trial of bimekizumab in psoriatic arthritis, which is a non-oncologic inflammatory condition. The primary and secondary endpoints are patient-reported outcomes (pain, fatigue, function, quality of life) and work productivity, not time-to-event efficacy endpoints (e.g., OS, PFS, DFS) with Kaplan-Meier or HR analysis as required for this cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Randomized Study of Consolidation Chemoradiotherapy Versus Observation After First-line Chemotherapy in Advanced Gallbladder Cancers: RACE-GB study. PMID 39675683 · Int J Radiat Oncol Biol Phys · 2025-May-01 The study is a randomized trial in advanced gallbladder cancer (oncology, human, malignant neoplasm) with a drug-containing intervention (capecitabine) and a primary time-to-event efficacy endpoint (OS). It is an original report of results. While the explicit phase is not stated in the metadata, the trial design (randomized comparison against observation as the standard of care) and the primary OS endpoint with significant results indicate a definitive (Phase III-level) randomized trial. All required criteria are explicitly established.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial. PMID 39656627 · J Natl Cancer Inst · 2025-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS. PMID 39437003 · Rheumatology (Oxford) · 2025-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML. PMID 40453133 · Blood Neoplasia · 2025-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Intraoperative indocyanine green fluorescence angiography in colorectal surgery to prevent anastomotic leakage: A single-blind phase III multicentre randomized controlled trial (FLUOCOL-01/FRENCH 21/GRECCAR 19 intergroup trial). PMID 40415381 · Colorectal Dis · 2025-May This is a Phase III randomized controlled trial protocol for a diagnostic/procedural intervention (indocyanine green fluorescence angiography) in colorectal surgery. The primary endpoint is anastomotic leak (a complication), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). It does not meet the required drug intervention or time-to-event endpoint criteria, and it is a protocol without reported results.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Impact of Providing an Automated Telephone Option to Report Weekly Patient-Reported Outcome Measures in the PRO-TECT Trial (AFT-39) on Disparity Gaps in Symptom Management and Outcomes. PMID 40408610 · JCO Clin Cancer Inform · 2025-May The study is a randomized oncology trial with original results, but it does not involve a drug-containing intervention (it tests a PROM reporting system) and does not have a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS) as a main focus, with only survival mentioned as an exploratory outcome at 12 months without detailed KM or HR results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Systematic Review. PMID 40403200 · JCO Glob Oncol · 2025-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II study. PMID 40359707 · ESMO Open · 2025-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Early switch from run-in with targeted to immunotherapy in advanced BRAFV600-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial. PMID 40345056 · ESMO Open · 2025-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Idarubicin versus Epirubicin in Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma: An Open-label, Randomized, Phase IV Trial. PMID 40326873 · Radiology · 2025-May 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
B
仅广召回影子组 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM). PMID 40311183 · ESMO Open · 2025-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): long-term follow-up of a randomised controlled, phase 2-3 trial. PMID 40291346 · EClinicalMedicine · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Plain language summary of first-line amivantamab-lazertinib in previously untreated high-risk EGFR-altered non-small-cell lung cancer in MARIPOSA. PMID 40270251 · Future Oncol · 2025-May Title indicates an oncology drug study, but the provided metadata (title, publication types, keywords, deterministic review) does not explicitly establish the presence of a time-to-event efficacy endpoint, randomization, phase, human subject status, or that this is an original result report. The record is a 'plain language summary' which is not a formal primary result report.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma. PMID 40253943 · Lung Cancer · 2025-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial. PMID 40239366 · ESMO Open · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Randomized phase 2 trial of pembrolizumab alone or in combination with low dose chemotherapy for patients with non-small cell lung cancer and poor performance status. PMID 40203764 · Lung Cancer · 2025-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial. PMID 40195451 · Nat Med · 2025-May The study is a randomized, controlled trial in oncology with a time-to-event endpoint (PFS). However, the provided metadata does not explicitly establish the trial phase as Phase III or Phase II/III. The publication types do not include a phase designation, and the abstract does not mention Phase III. Therefore, it does not meet the required phase criterion for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Photobiomodulation for the prevention of oral side effects secondary to head and neck cancer therapy: results of a randomised, single-blind clinical trial. PMID 40184883 · Oral Oncol · 2025-May The study is an oncology randomized trial in humans with original results, but it evaluates a non-drug intervention (photobiomodulation/light therapy) and focuses on supportive care endpoints (e.g., oral mucositis, pain), not a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitors. PMID 40174385 · Lung Cancer · 2025-May Cannot confirm primary/key secondary time-to-event efficacy endpoint from provided metadata; requires review of full text.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Patient Navigation to Improve Colonoscopy Completion After an Abnormal Stool Test Result : A Randomized Controlled Trial. PMID 40163863 · Ann Intern Med · 2025-May This is an oncology-related (colorectal cancer early detection) randomized controlled trial, but it evaluates a non-drug intervention (patient navigation) and lacks a Phase III classification and a time-to-event efficacy endpoint (OS, PFS, etc.) with Kaplan-Meier or HR reporting.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study. PMID 40148673 · Dermatol Ther (Heidelb) · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305. PMID 40075025 · Adv Ther · 2025-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
B
影子组漏检补回 eligibleexplicit_phase3_randomized confirmed 2 Figure · 4 Panel · risk visible
Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO-1, PSO-4, and LTE trials. PMID 40066907 · J Dermatol · 2025-May The record describes a phase 3 randomized trial of deucravacitinib in plaque psoriasis. While it meets criteria for being a phase 3, randomized, human, drug-intervention study with original results, it is excluded because psoriasis is not a human malignant neoplasm (oncology) and the study does not report a primary/key secondary time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. PMID 40055522 · Nat Med · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Reply to Letter to the Editor: 'A phase III randomised trial on the addition of a contact x-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 years results of the OPERA trial' by J. Meyer, T. Koessler. PMID 40037944 · Ann Oncol · 2025-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Inhaled alone versus inhaled plus intravenous polymyxin B for the treatment of pneumonia due to carbapenem-resistant gram-negative bacteria: A prospective randomized controlled trial. PMID 40023452 · Int J Antimicrob Agents · 2025-May The study is a randomized controlled trial of an antibiotic (Polymyxin B) for pneumonia caused by carbapenem-resistant Gram-negative bacteria. While it includes patients with malignancies as a prognostic factor, the study is not primarily an oncology trial, its phase is not defined as definitive (III/IIIb or II/III), and it lacks the required time-to-event primary efficacy endpoint (e.g., OS, PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study. PMID 40016055 · Eur Urol · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Cognitive behavioral stress management effects on cancer-related distress and neuroendocrine signaling in breast cancer: differential effects by neighborhood disadvantage. PMID 39966311 · Breast Cancer Res Treat · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Comment on: A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial. PMID 39956438 · Ann Oncol · 2025-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -